^
BIOMARKER:

Chr amplification(1q)

News
Twitter
Trials
Chr amplification(1q)
Multiple Myeloma
VRD
Resistant: B - Late Trials
Chr amplification(1q)
Multiple Myeloma
lenalidomide + ixazomib
Sensitive: C3 – Early Trials
Chr amplification(1q)
Multiple Myeloma
lenalidomide + carfilzomib
Resistant: C3 – Early Trials
Chr amplification(1q)
Multiple Myeloma
bortezomib
Resistant: C3 – Early Trials
Chr amplification(1q)
Multiple Myeloma
venetoclax
Resistant: D – Preclinical